In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanosyn Inc.

Latest From Nanosyn Inc.

Dealmaking Along the Faultlines

Big Pharma's valuations are depressed; biotech is red-hot. Alliance volumes have fallen, but average deal values are up. The valuation divide masks the subtler cracks dividing biotech's elite from a mass of undifferentiated technology providers. Drug companies are recognizing that basing discovery programs around new, proprietary targets is highly risky and lengthens R&D time. Targets themselves, absent optimized lead compounds, are increasingly commoditized. Therefore, companies who don't provide integrated discovery capabilities aren't going to get the high-value deals that will justify their current, sky-high valuations. Meanwhile, companies with integrated solutions must back up their promises of productivity enhancement with their own money--though they also get a richer share of the end proceeds.
BioPharmaceutical Strategy

After executives at drug discovery firm Arena Pharmaceuticals went through the laborious and time-consuming process of contacting suppliers to assemble a large library of chemical compounds for screening, they knew there must be a better way. They thus hit upon the idea of an e-procurement business to supply compounds for pharmaceutical lead optimization, forming Inc. in 1999. is the first e-commerce company to aggregate global suppliers of chemical compounds for drug discovery, its founders believe.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Nanoscale Combinatorial Synthesis Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nanosyn Inc.
  • Senior Management
  • Nikolai Sepetov, PhD, Pres. & CEO
  • Contact Info
  • Nanosyn Inc.
    Phone: (650) 853-7034
    3603 Haven Ave.
    Ste. E
    Menlo Park, CA 94025